(MENAFN- GetNews)
"Migraine Pipeline"Migraine companies are Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, Tonix Pharmaceuticals, BetterLife Pharma, and others.
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Migraine pipeline constitutes 30+ key companies continuously working towards developing 30+ Migraine treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Migraine Pipeline Insight, 2024"
report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.
The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Migraine Pipeline Analysis
Some of the key takeaways from the Migraine Pipeline Report:
Migraine Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years.
Migraine companies working in the treatment market are Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, Tonix Pharmaceuticals, BetterLife Pharma, and others, are developing therapies for the Migraine treatment
Emerging Migraine therapies such as AXS-07, STS-101, Zavegepant, TNX1900 and others are expected to have a significant impact on the Migraine market in the coming years. On April 2024, AbbVie announced results of a Randomized, Double-Blind, Parallel-Group, and Active Controlled Trial with Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE). On April 2024, Pfizer announced results of a Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens. On November 2023, AbbVie announced results of a Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, and Parallel-Group Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine.
Migraine Overview
Migraine, a neurological disorder characterized by recurrent headaches, affects millions worldwide. These debilitating headaches are often accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound.
Understanding the complexity of migraines involves delving into various factors, including genetic predisposition, environmental triggers, and neurotransmitter imbalances. While the exact cause remains elusive, research suggests that changes in the brainstem and its interactions with the trigeminal nerve play a crucial role in migraine onset.
Managing migraines encompasses a multifaceted approach, ranging from lifestyle modifications to pharmacological interventions. From over-the-counter pain relievers to preventive medications, treatment strategies aim to alleviate symptoms and improve quality of life for migraine sufferers.
As awareness grows, so does the pursuit of innovative therapies. Ongoing research into novel drugs and neuromodulation techniques offers hope for more effective migraine management in the future.
Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment-
Migraine Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal
Migraine Molecule Type
Migraine Products have been categorized under various Molecule types, such as
Oligonucleotide Peptide Small molecule
Migraine Pipeline Therapeutics Assessment
Migraine Assessment by Product Type Migraine By Stage and Product Type Migraine Assessment by Route of Administration Migraine By Stage and Route of Administration Migraine Assessment by Molecule Type Migraine by Stage and Molecule Type
DelveInsight's Migraine Report covers around 30+ products under different phases of clinical development like-
Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration
Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the
emerging Migraine therapies -
Migraine Pipeline Analysis:
The Migraine pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment. Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.
Download Sample PDF Report to know more about
Migraine drugs and therapies-
Scope of Migraine Pipeline Drug Insight
Coverage: Global Key Migraine Companies:
Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, Tonix Pharmaceuticals, BetterLife Pharma, and others. Key Migraine Therapies:
AXS-07, STS-101, Zavegepant, TNX1900 and others. Migraine Therapeutic Assessment:
Migraine current marketed and Migraine emerging therapies Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
Request for Sample PDF Report for
Migraine Pipeline Assessment and clinical trials-
Table of Contents
1. Migraine Report Introduction
2. Migraine Executive Summary
3. Migraine Overview
4. Migraine- Analytical Perspective In-depth Commercial Assessment
5. Migraine Pipeline Therapeutics
6. Migraine Late Stage Products (Phase II/III)
7. Migraine Mid Stage Products (Phase II)
8. Migraine Early Stage Products (Phase I)
9. Migraine Preclinical Stage Products
10. Migraine Therapeutics Assessment
11. Migraine Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Migraine Companies
14. Migraine Key Products
15. Migraine Unmet Needs
16 . Migraine Market Drivers and Barriers
17. Migraine Future Perspectives and Conclusion
18. Migraine Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
MENAFN29042024003238003268ID1108153800
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.